1
|
Lu PH, Ma PW, Wang WL, Gao W, Chen JW, Yuan H, Ding XR, Lun YQ, Liang R, Li SY, Wang Z, Guo JN, Mei HK, Lu LJ. Deferoxamine protects cochlear hair cells and hair cell-like HEI-OC1 cells against tert-butyl hydroperoxide-induced ototoxicity. Biochim Biophys Acta Mol Basis Dis 2024; 1870:167024. [PMID: 38242180 DOI: 10.1016/j.bbadis.2024.167024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 11/30/2023] [Accepted: 01/08/2024] [Indexed: 01/21/2024]
Abstract
Oxidative stress is the common mechanism of sensorineural hearing loss (SNHL) caused by many factors, such as noise, drugs and ageing. Here, we used tert-butyl hydroperoxide (t-BHP) to cause oxidative stress damage in HEI-OC1 cells and in an in vitro cochlear explant model. We observed lipid peroxidation, iron accumulation, mitochondrial shrinkage and vanishing of mitochondrial cristae, which caused hair cell ferroptosis, after t-BHP exposure. Moreover, the number of TUNEL-positive cells in cochlear explants and HEI-OC1 cells increased significantly, suggesting that t-BHP caused the apoptosis of hair cells. Administration of deferoxamine (DFOM) significantly attenuated t-BHP-induced hair cell loss and disordered hair cell arrangement in cochlear explants as well as HEI-OC1 cell death, including via apoptosis and ferroptosis. Mechanistically, we found that DFOM treatment reduced t-BHP-induced lipid peroxidation, iron accumulation and mitochondrial pathological changes in hair cells, consequently mitigating apoptosis and ferroptosis. Moreover, DFOM treatment alleviated GSH depletion caused by t-BHP and activated the Nrf2 signalling pathway to exert a protective effect. Furthermore, we confirmed that the protective effect of DFOM mainly depended on its ability to chelate iron by constructing Fth1 knockout (KO), TfR1 KO and Nrf2 KO HEI-OC1 cell lines using CRISPR/Cas9 technology and a Flag-Fth1 (overexpression) HEI-OC1 cell line using the FlpIn™ System. Our findings suggest that DFOM is a potential drug for SNHL treatment due to its ability to inhibit apoptosis and ferroptosis by chelating iron and scavenging reactive oxygen species (ROS).
Collapse
Affiliation(s)
- Pei-Heng Lu
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Peng-Wei Ma
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Wei-Long Wang
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Wei Gao
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Jia-Wei Chen
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Hao Yuan
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Xue-Rui Ding
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Yu-Qiang Lun
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Rui Liang
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Si-Yu Li
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Zi Wang
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Jia-Ning Guo
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Hong-Kai Mei
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China
| | - Lian-Jun Lu
- Department of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
| |
Collapse
|
2
|
Wang Y, Wu N, Wang K, Liao Y, Guo J, Zhong B, Guo T, Liang J, Jiang N. Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study. Front Genet 2022; 13:955133. [PMID: 36118857 PMCID: PMC9479159 DOI: 10.3389/fgene.2022.955133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 08/10/2022] [Indexed: 11/13/2022] Open
Abstract
Objective: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer (PC) that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. In our investigation, there appeared to be a strong correlation between neuroendocrine differentiation prostate cancer (NEDPC) and NEPC. The objectives of this study included exploring whether NEDPC is an intermediate stage in the progression of high-risk prostate cancer (HRPC) to NEPC and identifying risk factors and new targets associated with survival in the treatment of NEPC.Methods: The selected prostate cancer patients were progressed to high-risk and characterized by neuroendocrine. We collected the clinical data and characteristics of patients with three types of cancer: the incidence of metastasis, site and time of metastasis, recurrence rate, related treatment methods, etc. The similarity and differences of the three groups were compared through experiment and database.Results: By analyzing the clinical data and immunohistochemical results, we found that there seems to be a clinical feature of neuroendocrine differentiation (NED) status in between when patients progress from PC to NEPC. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC. The metastasis-free survival curve and the immunohistochemical results are informing us that NEDPC can be a pre-state for diagnosing NEPC.Conclusion: NEPC is a late PC symptom that is frequently disregarded and has a bad prognosis. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC.
Collapse
Affiliation(s)
- YouZhi Wang
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Ning Wu
- Key Laboratory of Breast Cancer Prevention and Therapy, State Ministry of Education, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin Medical University Cancer Hospital and Institute, Tianjin, China
| | - KeKe Wang
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - YiHao Liao
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - JiaNing Guo
- Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - BoQiang Zhong
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Tao Guo
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - JiaMing Liang
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Ning Jiang
- Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China
- *Correspondence: Ning Jiang,
| |
Collapse
|
3
|
Yu Z, Liu Y, Guo JN, Yuan YQ, Li ZS, Yuan Q, Liu YF, Zhao CB, Fang JQ, Xiao KF. Establishment of a model for predicting Gleason score >7 before prostate biopsy. J BIOL REG HOMEOS AG 2019; 33:1113-1118. [PMID: 31389222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
- Z Yu
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - Y Liu
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - J N Guo
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - Y Q Yuan
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - Z S Li
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - Q Yuan
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - Y F Liu
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - C B Zhao
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - J Q Fang
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| | - K F Xiao
- Department of Urology, Shenzhen People's Hospital, the Second Affiliated Hospital of Jinan University, Shenzhen, China
| |
Collapse
|
4
|
Guo JN, Li H, Hu ZD, Liang EL, Chang JW. [Clinicopathological features of primary seminal vesicle adenocarcinoma: A report of 4 cases and review of the literature]. Zhonghua Nan Ke Xue 2017; 23:639-645. [PMID: 29723459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To investigate the clinicopathological characteristics, diagnosis, and treatment of primary seminal vesicle adenocarcinoma (SVAC). METHODS We analyzed the clinical data and clinicopathological characteristics of 4 cases of primary SVAC treated in the Department of Urology of the Second Hospital of Tianjin Medical University and reviewed relevant literature. RESULTS All the 4 patients were treated by open radical resection of the seminal vesicle and prostate and pathologically diagnosed with SVAC. Preoperative prostatic biopsy had shown 1 of the cases to be negative, while preoperative CT and transrectal ultrasound had revealed a huge pelvic cystic neoplasm in another patient. Immunohistochemistry manifested that the 4 cases were all negative for prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and cytokeratin 20 (CK20), but positive for cancer antigen 125 (CA125) and CK7. All the patients recovered smoothly after surgery and experienced no recurrence or metastasis during 154, 41, 20, and 12 months of follow-up. CONCLUSIONS Primary seminal vesicle carcinoma is extremely rare and presents in an advanced stage. Immunohistochemistry plays a valuable role in its differential diagnosis. Various combinations of radical surgery, radiotherapy, androgen-deprivation therapy, and chemotherapy are recommended for the treatment of the disease.
Collapse
Affiliation(s)
- Jia-Ning Guo
- Tianjin Research Institute of Urology / Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Hui Li
- Department of Clinical Laboratory, Tianjin Tumor Hospital, Tianjin 300000, China
| | - Zhan-Dong Hu
- Department of Pathology, Tianjin First Central Hospital, Tianjin 300000, China
| | - En-Li Liang
- Tianjin Research Institute of Urology / Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Ji-Wu Chang
- Tianjin Research Institute of Urology / Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|